

14. Ohki T, Yamato M, Ota M, Takagi R, Murakami D, Kondo M, Sasaki R, Namiki H, Okano T, Yamamoto M, 3: Prevention of esophageal stricture after endoscopic submucosal dissection using tissue-engineered cell sheets. *Gastroenterology* 2012, **143**:582–588–e581–582.
15. Sawa Y, Miyagawa S, Sakaguchi T, Fujita T, Matsuyama A, Saito A, Shimizu T, Okano T: Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case. *Surg Today* 2012, **42**(2):181–184.
16. Kaneshiro N, Sato M, Ishihara M, Mitani G, Sakai H, Kikuchi T, Mochida J: Cultured articular chondrocytes sheets for partial thickness cartilage defects utilizing temperature-responsive culture dishes. *Eur Cell Mater* 2007, **13**:87–92.
17. Mitani G, Sato M, Lee JI, Kaneshiro N, Ishihara M, Ota N, Kokubo M, Sakai H, Kikuchi T, Mochida J: The properties of bioengineered chondrocyte sheets for cartilage regeneration. *BMC Biotechnol* 2009, **9**:17.
18. Ebihara G, Sato M, Yamato M, Mitani G, Kutsuna T, Nagai T, Ito S, Ukai T, Kobayashi M, Kokubo M, et al: Cartilage repair in transplanted scaffold-free chondrocyte sheets using a minipig model. *Biomaterials* 2012, **33**(15):3846–3851.
19. Memon IA, Sawa Y, Fukushima N, Matsumiya G, Miyagawa S, Taketani S, Sakakida SK, Kondoh H, Aleshin AN, Shimizu T, et al: Repair of impaired myocardium by means of implantation of engineered autologous. *J Thorac Cardiovasc Surg* 2005, **130**(5):1333–1341.
20. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, et al: Monolayered mesenchymal stem cells repair scarred myocardium after myocardial. *Nat Med* 2006, **12**(4):459–465.
21. Kito K, Kagami H, Kobayashi C, Ueda M, Terasaki H: Effects of cryopreservation on histology and viability of cultured corneal epithelial cell sheets in rabbit. *Cornea* 2005, **24**(6):735–741.
22. Kuwayama M, Vajta G, Kato O, Leibso SP: Highly efficient vitrification method for cryopreservation of human oocytes. *Reprod Biomed Online* 2005, **11**(3):300–308.
23. Saragusty J, Arav A: Current progress in oocyte and embryo cryopreservation by slow freezing and vitrification. *Reproduction* 2011, **141**(1):1–19.
24. Parks JE, Ruffing NA: Factors affecting low-temperature survival of mammalian oocytes. *Theriogenology* 1992, **37**(1):59–73.
25. Polge C, Wilmut I, Rowson L: The low temperature preservation of cow, sheep and pig embryos. *Cryobiology* 1974, **11**(6):560.
26. Wilmut I: The low temperature preservation of mammalian embryos. *J Reprod Fertil* 1972, **31**:513–514.
27. Nagashima H, Kashiwazaki N, Ashman RJ, Grupen CG, Nettle MB: Cryopreservation of porcine embryos. *Nature* 1995, **374**(6521):416.
28. Nagashima H, Yamakawa H, Niemann H: Freezability of porcine blastocysts at different peri-hatching stages. *Theriogenology* 1992, **37**(4):839–850.
29. Matsunari H, Maehara M, Nakano K, Ikezawa Y, Hagiwara Y, Sasayama N, Shirasu A, Ohta H, Takahashi M, Nagashima H: Hollow Fiber Vitrification: a novel method for vitrifying multiple embryos in a single device. *J Reprod Dev* 2012, **58**(5):599–608.
30. Maehara M, Matsunari H, Honda K, Nakano K, Takeuchi Y, Kanai T, Matsuda T, Matsumura Y, Hagiwara Y, Sasayama N, et al: Hollow Fiber Vitrification Provides a Novel Method for Cryopreserving In Vitro Maturation/Fertilization-Derived Porcine Embryos. *Biol Reprod* 2012, **87**(6):133, 1–8.
31. Hamawaki A, Kuwayama M, Hamano S: Minimum volume cooling method for bovine blastocyst vitrification. *Theriogenology* 1999, **51**(1):165.
32. Kuwayama M: Highly efficient vitrification for cryopreservation of human oocytes and embryos: The Cryotop method. *Theriogenology* 2007, **67**(1):73–80.
33. Matsumura K, Hyon SH: Polyampholytes as low toxic efficient cryoprotective agents with antifreeze protein properties. *Biomaterials* 2009, **30**(27):4842–4849.
34. Mazur P, Seki S: Survival of mouse oocytes after being cooled in a vitrification solution to -196°C at 95° to 70,000°C/min and warmed at 610° to 118,000°C/min: A new paradigm for cryopreservation by vitrification. *Cryobiology* 2011, **62**(1):1–7.
35. Seki S, Mazur P: The dominance of warming rate over cooling rate in the survival of mouse oocytes subjected to a vitrification procedure. *Cryobiology* 2009, **59**(1):75–82.
36. Rall WF, Fahy GM: Ice-free cryopreservation of mouse embryos at -196°C by vitrification. *Nature* 1985, **313**(6003):573–575.
37. Hamahashi K, Sato M, Yamato M, Kokubo M, Mitani G, Ito S, Nagai T, Ebihara G, Kutsuna T, Okano T, et al: Studies of the humoral factors produced by layered chondrocyte sheets. *J Tissue Eng Regen Med* 2012. <http://dx.doi.org/10.1002/term.1610>.

doi:10.1186/1472-6750-13-58

Cite this article as: Maehara et al.: Development of a novel vitrification method for chondrocyte sheets. *BMC Biotechnology* 2013 **13**:58.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit





Transgenic Pig Expressing the Red Fluorescent Protein Kusabira-Orange as a Novel Tool for Preclinical Studies on Hepatocyte Transplantation

T. Shigeta, H.-C. Hsu, S. Enosawa, N. Matsuno, M. Kasahara, H. Matsunari, K. Umeyama, M. Watanabe, and H. Nagashima

ABSTRACT

Introduction. Research on hepatocyte transplantation as an alternative or supplementary treatment for liver transplantation is progressing. However, to advance to clinical trials, confidence in the technique must be established and its safety must be validated by conducting experiments using animals of comparable sizes to humans, such as pigs. We used transgenic pigs expressing red fluorescence protein for investigating the distribution and survival of transplanted cells.

Materials and Methods. Donor hepatocytes were isolated from transgenic Kusabira-Orange (KO)-expressing pigs (age, 41 days; weight, 10 kg) created by *in vitro* fertilization using sperm from a transgenic-cloned KO pig by Matsunari et al. and ova from a domestic pig. The hepatocyte transplant recipients were the nontransgenic, KO-negative littermates. In these recipient pigs, double lumen cannulae were inserted into the supramesenteric veins to access the hepatic portal region. KO-positive donor hepatocytes from the transgenic male pig were isolated using collagenase perfusion. Hepatocytes (1×10^9 cells) were transplanted through the cannula. For estimating allogeneic immunogenicity, full-thickness skin (3×3 cm) from the same donor was grafted orthotopically on the neck region of the recipients. Immunosuppressive treatment was not implemented. The recipient pigs were humanely killed at 7 and 39 days after transplantation, and the organs were harvested, including the lungs, heart, liver, pancreas, and kidneys.

Results. Strong red fluorescence was detected in both the parenchymal and nonparenchymal hepatocytes of the transgenic male donor pig by fluorescent microscopy. Transplanted cells were detected in the liver and lung of the recipient pigs at 7 days after perfusion. Hepatocytes remained in the liver and lung of recipients on day 39, with lower numbers than that on day 7.

Conclusion. Transgenic pigs expressing the fluorescent protein KO serve as a useful model of cell transplantation in preclinical studies.

HEPATOCYTE transplantation (HCT) is considered to be an alternative or supplementary treatment for liver transplantation (LT) in urea cycle disorders (UCD), including ornithine transcarbamylase deficiency and carbamyl phosphate synthetase 1 deficiency, in addition to acute liver failure (ALF).^{1,2} HCT has many advantages compared with LT. For instance, it is less invasive, feasible as a partial or temporal liver support for metabolic disease or ALF, could be supplied from a marginal graft, and could be ready-to-use on demand.¹⁻⁴ However, HCT research is at the pioneering stage, despite increasing numbers of case reports for clinical HCT.^{1,5-10} Moreover, because UCD is

From the Transplantation Center (T.S., M.K.), Clinical Research Center (H.-C.H., S.E., N.M.), National Center for Child Health and Development, Tokyo, Japan, and International Institute for Bio-Resource Research (H.M., K.U., M.W., H.N.), Meiji University, Tokyo, Japan.

Address reprint requests to Shin Enosawa, PhD, Division for Advanced Medical Sciences, Clinical Research Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya, Tokyo 157-8535, Japan. E-mail: enosawa-s@ncchd.go.jp

most common in neonatal patients, size mismatches of liver grafts represent a major problem at the time of LT. Therefore, these patients must wait until reaching about 7 kg.¹⁰⁻¹² During the waiting time for LT, patients are at risk of hyperammonemia, developing severe neurological impairments, or lethal coma.^{2,12,13} Thus, HCT can be performed to prevent such problems in the treatment of UCD and ALF as a bridge to LT. To advance to clinical trials, confidence in the technique must be established and its safety must be validated by conducting experiments using animals of comparable sizes to humans, such as pigs. This study shows the use of transgenic pigs expressing red fluorescence to investigate the distribution and survival of transplanted cells.

MATERIALS AND METHODS

Donor hepatocytes were isolated from transgenic Kusabira-Orange (KO)-expressing pigs (age, 41 days; weight, 10 kg) created by in vitro fertilization using the sperm from a transgenic-cloned KO male pig by Matsunari et al. and ova of a domestic pig.¹⁴

KO-positive donor hepatocytes were isolated from the male transgenic pig by collagenase (032-10534 Wako Pure Chemicals, Osaka, Japan) perfusion; furthermore, the parenchymal hepatocytes were obtained through low-speed centrifugation (50 g, 1 minute, 3 times).^{15,16}

Two offspring (recipients) that were nontransgenic, KO-negative littermates, were used in this study. Under isoflurane anesthesia, minimal abdominal midline incisions were made in both of the recipient pigs. Then, double lumen cannulae (18 gauge; Medicut LCV-UK; Tyco Healthcare, NJ, United States) were inserted into the supramesenteric veins of both the pigs, to access the portal vein trunk. The proximal end was used for portal pressure assessment, whereas the distal end was used for HCT. Hepatocytes (1×10^9 suspended in 100 mL saline containing 5 U/mL heparin) were transplanted once through the cannulae. To estimate allogeneic immunogenicity, full-thickness skin (3×3 cm) from the same male donor was grafted orthotopically onto the neck region of the nontransgenic recipient pigs. Immunosuppressive treatment was not implemented. The 2 recipient pigs were humanely killed at 7 (recipient 1) and 39 (recipient 2) days after transplantation, and the organs were harvested for examination, including the lungs, heart, liver, pancreas, and kidneys. Isolated organ specimens were sliced

into 5- to 10-mm pieces, and observed using fluorescent microscopy.

RESULTS

Strong red fluorescence was detected in both the parenchymal and nonparenchymal hepatocytes of the male transgenic donor pig using fluorescent microscopy (Fig 1). Multiple transplanted cells were detected in the liver and lung of recipient 1, whereas the skin graft was rejected within 7 days. Hepatocytes remained in the lung and liver of recipient 2 for 39 days, with a lower number than that in recipient 1. While the skin graft was acutely rejected, the hepatocytes remained for up to 39 days. KO-positive hepatocytes were not detected in the heart, pancreas, or kidney, and no obvious ischemic change was observed on the liver surface of either recipient.

DISCUSSION

To our knowledge, this report shows the first record of using KO-transgenic hepatocytes for HCT experiments. Matsunari et al produced transgenic-cloned pigs carrying a humanized KO gene, which is a newly developed red fluorescent protein.¹⁴ KO was cloned from the mushroom coral *Fungia concinna*, which yields orange-red fluorescence in its dimeric form and has 558 and 583 nm excitation and emission maxima, respectively.¹⁷ In addition to KO transgenic pigs, transgenic pigs expressing enhanced green fluorescent protein (EGFP) were studied.¹⁸ As a major feature, KO showed minor background autofluorescence in the liver and lung of humanized KO transgenic pigs compared with EGFP transgenic animals, in which the organs are known to exhibit autofluorescence.^{19,20} Furthermore, the clear red fluorescence of the humanized KO protein is maintained even in paraffin-embedded tissue sections.¹⁴

In our study, lung distribution was identified, although there was no obvious presentation of pulmonary embolization. Interestingly, only a few studies have documented the possibility of pulmonary embolization after HCT.^{1,8,21} Muraca et al showed that hepatocytes remained in the lung sinusoids for up to 48 hours after infusion in all pigs;




Fig 1. (a) Fluorescent microscopy images showing strong red fluorescence in both parenchymal and nonparenchymal hepatocytes of the transgenic donor pig. Transplanted KO-expressing transgenic hepatocytes were detected 1 week after hepatocyte transplantation (b) in the liver and (c) lung. Transplanted KO-expressing transgenic hepatocytes were detected about 1 month after hepatocyte transplantation (d) in the liver and (e) lung.

furthermore, a minor basal pulmonary infarction was identified in one of the pigs.²¹ In addition, they showed that the number of infused cells was directly correlated with increased portal pressure, but not increased pulmonary artery pressure. They suggested that local vasoconstriction might contribute to the observed increase in pulmonary artery pressure after HCT. Bilir et al reported that intraportal HCT in patients with ALF was followed by hypoxia and pulmonary infiltrates in chest cardiographs, both of which improved after 24 hours.¹ In clinical HCT, hepatocytes were infused several times; hence, portal vein complication represents a serious complication.^{5,8,21} In addition, there is a risk of pulmonary embolism due to the repeated infusion of hepatocytes, despite only a small number of hepatocytes passing through the liver. There was no evidence of the intrapulmonary shunt causing a problem to the experimental pigs. However, the safety of intraportal HCT requires further improvement, along with further investigations about the risk of pulmonary embolization. KO hepatocytes remained in the liver and lung for about 1 month. However, our study had a limitation in that we could not identify whether these hepatocytes were functional. Therefore, experiments using animal disease models should be considered in future studies.

Analysis of antigenicity of the donor-recipient combinations in the current study indicated that KO was xenogeneic, whereas somatic cells were allogeneic. Because KO is an intracellular protein, xenogeneic antigenicity might not accelerate normal allogeneic rejection. Immunosuppressive treatment might induce extended survival. One major problem in the clinical application of HCT is the low survival rate of donor cells. It has been hypothesized that the quick disappearance of HCT cells is due to a nonspecific inflammatory response or instant blood-mediated inflammatory reaction (IBMIR); however, the precise mechanisms require clarification.²² The transgenic pigs used here might serve as a conclusive research tool to overcome the deficit in information, as well as toward improving the cell transplantation procedure. In addition, identical clones of nontransgenic and transgenic littermates obtained by the nuclear transfer methodology might help create a more simple research model for IBMIR research focus.²³ In conclusion, the transgenic pig expressing fluorescent protein KO provides a useful model in cell transplantation preclinical studies.

REFERENCES

1. Bilir BM, Guinette D, Karrer F, et al. Hepatocyte transplantation in acute liver failure. *Liver Transpl*. 2000;6:32–40.
2. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. *Pediatrics*. 2003;111:1262–1267.
3. Puppi J, Strom SC, Hughes RD, et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. *Cell Transplant*. 2012;21:1–10.
4. Hughes RD, Mitry RR, Dhawan A, et al. Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation. *Liver Transpl*. 2006;12:713–717.
5. Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver diseases. *Pediatr Transplant*. 2008;12:6–13.
6. Puppi J, Tan N, Mitry RR, et al. Hepatocyte transplantation followed by auxiliary liver transplantation—a novel treatment for ornithine transcarbamylase deficiency. *Am J Transplant*. 2008;8:452–457.
7. Fitzpatrick E, Mitry RR, Dhawan A. Human hepatocyte transplantation: state of the art. *J Intern Med*. 2009;266:339–357.
8. Meyburg J, Hoffmann GF. Liver cell transplantation for the treatment of inborn errors of metabolism. *J Inherit Metab Dis*. 2008;31:164–172.
9. Meyburg J, Schmidt J, Hoffmann GF. Liver cell transplantation in children. *Clin Transplant*. 2009;23:75–82.
10. Kasahara M, Fukuda A, Yokoyama S, et al. Living donor liver transplantation with hyperreduced left lateral segments. *J Pediatr Surg*. 2008;43:1575–1578.
11. Kasahara M, Sakamoto S, Shigeta T, et al. Reducing the thickness of left lateral segment grafts in neonatal living donor liver transplantation [e-pub ahead of print]. *Liver Transpl*. 2013;19:226–228.
12. Kasahara M, Sakamoto S, Shigeta T, et al. Living-donor liver transplantation for carbamoyl phosphate synthetase 1 deficiency. *Pediatr Transplant*. 2010;14:1036–1040.
13. McBride KL, Miller G, Carter S, et al. Developmental outcomes with early orthotopic liver transplantation for infants with neonatal-onset urea cycle defects and a female patient with late-onset ornithine transcarbamylase deficiency. *Pediatrics*. 2004;114:e523–526.
14. Matsunari H, Onodera M, Tada N, et al. Transgenic-cloned pigs systemically expressing red fluorescent protein, Kusabira-Orange. *Cloning Stem Cells*. 2008;10:313–323.
15. Seglen PO. Preparation of isolated rat liver cells. *Methods Cell Biol*. 1976;13:29–83.
16. Enosawa S, Yuan W, Douzen M, et al. Consideration of a safe protocol for hepatocyte transplantation using infantile pigs. *Cell Med*. 2012;3:13–18.
17. Karasawa S, Araki T, Nagai T, et al. Cyan-emitting and orange-emitting fluorescent proteins as a donor/acceptor pair for fluorescence resonance energy transfer. *Biochem J*. 2004;381:307–312.
18. Kawarasaki T, Uchiyama K, Hirao A, et al. Profile of new green fluorescent protein transgenic Jinhua pigs as an imaging source. *J Biomed Opt*. 2009;14:054017.
19. Miyawaki A. Green fluorescent protein-like proteins in reef Anthozoa animals. *Cell Struct Funct*. 2002;27:343–347.
20. Vintersten K, Monetti C, Gertsenstein M, et al. Mouse in red: red fluorescent protein expression in mouse ES cells, embryos, and adult animals. *Genesis*. 2004;40:241–246.
21. Muraca M, Neri D, Parenti A, et al. Intraportal hepatocyte transplantation in the pig: hemodynamic and histopathological study. *Transplantation*. 2002;73:890–896.
22. Gustafson EK, Elgue G, Hughes RD, et al. The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. *Transplantation*. 2011;91:632–638.
23. Matsunari H, Nagashima H. Application of genetically modified and cloned pigs in translational research. *J Reprod Dev*. 2009;55:225–230.

—Technology Report—

Production of Diabetic Offspring Using Cryopreserved Epididymal Sperm by *In Vitro* Fertilization and Intrafallopian Insemination Techniques in Transgenic Pigs

Kazuhiro UMEYAMA^{1,2}, Kasumi HONDA¹, Hitomi MATSUNARI^{1,2}, Kazuaki NAKANO¹, Tatsuro HIDAKA¹, Keito SEKIGUCHI¹, Hironori MOCHIZUKI¹, Yasuhiro TAKEUCHI¹, Tsukasa FUJIWARA¹, Masahito WATANABE^{1,2}, Masaki NAGAYA² and Hiroshi NAGASHIMA^{1,2}

¹Laboratory of Developmental Engineering, Department of Life Sciences, School of Agriculture, Meiji University, Kanagawa 214-8571, Japan

²Meiji University International Institute for Bio-Resource Research, Kanagawa 214-8571, Japan

Abstract. Somatic cell nuclear transfer (SCNT) is a useful technique for creating pig strains that model human diseases. However, production of numerous cloned disease model pigs by SCNT for large-scale experiments is impractical due to its complexity and inefficiency. In the present study, we aimed to establish an efficient procedure for proliferating the diabetes model pig carrying the mutant human hepatocyte nuclear factor-1 α gene. A founder diabetes transgenic cloned pig was generated by SCNT and treated with insulin to allow for normal growth to maturity, at which point epididymal sperm could be collected for cryopreservation. *In vitro* fertilization and intrafallopian insemination using the cryopreserved epididymal sperm resulted in diabetes model transgenic offspring. These results suggest that artificial reproductive technology using cryopreserved epididymal sperm could be a practical option for proliferation of genetically modified disease model pigs.

Key words: Cryopreserved epididymal sperm, Diabetes model pigs, Intrafallopian insemination, *In vitro* fertilization, Transgenic offspring

(J. Reprod. Dev. 59: 599–603, 2013)

The physiology and anatomy of pigs closely resemble those of humans; for this reason, pigs are regarded as a large animal model that can produce experimental data that are easily extrapolated to humans [1]. In recent years, genetic modification techniques have been used to develop pig strains that model several human diseases [2, 3].

We created genetically modified (GM) pigs that exhibit the symptoms of diabetes similar to maturity onset diabetes of the young 3 (MODY3). The diabetic symptoms of the GM pigs were induced by the dominant-negative effect of a transgene, human mutant hepatocyte nuclear factor 1 alpha (HNF-1 α) [4]. In applying GM pigs to translational research, it must be ensured that enough animals can be supplied for experiments. Therefore, we aimed to establish an efficient procedure for proliferating our diabetes model pig by means of artificial reproductive technologies. In this study, the founder transgenic (Tg) cloned pig was generated by somatic cell nuclear transfer (SCNT) and treated with insulin to allow for normal growth to maturity, at which point epididymal sperm could be collected for cryopreservation.

Here, we report that *in vitro* fertilization (IVF) and intrafallopian insemination using cryopreserved epididymal sperm are useful options for reproducing the diabetes model pig. This reproductive system

can theoretically be applied to other GM pigs, thereby enhancing the utility of disease model GM pigs.

Porcine fetal fibroblast cells carrying mutant human HNF-1 α [4] were used to generate the founder Tg pigs by SCNT. SCNT was performed as described elsewhere using *in vitro* matured (IVM) oocytes as recipient cytoplasts [5]. In total, 333 SCNT embryos were generated and transferred to three estrus-synchronized gilts on day 1 or day 2; each recipient received 116, 109 or 108 embryos. The gilt that had received 116 embryos became pregnant and farrowed four Tg-cloned pigs. Three of the four piglets died within two days of birth for unidentified reasons or from being crushed by the recipient sow. The surviving piglet developed hyperglycemia (non-fasting blood glucose level: 374 mg/dl) at two weeks of age.

Administration of insulin started at three weeks of age, and the pig was raised for 15 months as the founder Tg-cloned boar. The non-fasting blood glucose level of the founder Tg-cloned boar was maintained at approximately 200 mg/dl by administration of a combination of regular insulin (Novolin R, Novo Nordisk, Bagsvaerd, Denmark) and long-acting insulin glargine (Lantus, Sanofi, Paris, France) (Table 1). The target blood glucose level was set higher than the normal blood glucose level for pigs (85–150 mg/dl) to avoid the risk of hypoglycemic coma.

The level of 1,5-anhydroglucitol (1,5-AG) in the founder Tg-cloned boar was lower than that in healthy pigs (Table 1), indicating that the animal developed hyperglycemia. By contrast, the levels of blood urea nitrogen (BUN) and of triglyceride (TG) in the blood during the insulin administration period were similar to those of healthy

Received: June 12, 2013

Accepted: July 15, 2013

Published online in J-STAGE: August 24, 2013

©2013 by the Society for Reproduction and Development

Correspondence: H Nagashima (e-mail: hnagas@isc.meiji.ac.jp)

Table 1. Biochemical parameters in the plasma of the diabetes model founder transgenic-cloned pig

		Control (n = 10)	Founder			
		Mean \pm SD	4 months ^a	8 months ^a	12 months ^a	13 months ^b
ALT	(U/l)	28.2 \pm 8.1	40.0	37.0	32.0	32.0
AST	(U/l)	24.8 \pm 10.4	26.0	27.0	24.0	16.0
TP	(g/dl)	7.4 \pm 0.7	6.7	6.5	6.1	6.5
TG	(mg/dl)	32.7 \pm 27.1	48.0	28.0	41.0	74.0
T-CHO	(mg/dl)	70.7 \pm 17.9	124.0	59.0	54.0	75.0
GLU	(mg/dl)	109.6 \pm 26.1	246.0	230.0	195.0	536.0
1,5-AG	(mg/dl)	5.1 \pm 1.8	-	1.2	1.1	1.0
BUN	(mg/dl)	9.9 \pm 1.8	15.6	10.1	12.8	27.1
CRE	(mg/dl)	1.6 \pm 0.5	0.8	1.5	1.4	1.5
Na	(mEq/l)	140.8 \pm 2.9	136.0	134.0	143.0	135.0
K	(mEq/l)	4.9 \pm 1.3	3.8	4.4	3.4	4.3
Cl	(mEq/l)	101.6 \pm 2.4	99.0	94.0	97.0	94.0

^a Treated with insulin. ^b Not treated with insulin. 1,5-AG, 1,5-anhydroglucitol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; Cl, chloride; CRE, creatinine; GLU, glucose; K, potassium; Na, sodium; T-CHO, total cholesterol; TG, triglyceride; TP, total protein.

pigs (Table 1).

The founder Tg-cloned boar grew steadily and reached a peak weight of 169 kg at 12 months. The growth rate during the period between 3.5 months and 11 months was 3.7 kg/week, which was consistent with that of healthy wild-type (WT) pigs (3.6 kg/week). When insulin administration was temporarily stopped at 13 months, the founder pig started to lose weight, non-fasting blood glucose levels reached 536 mg/dl and BUN and TG levels worsened (Table 1). Therefore, these analyses demonstrated that the founder Tg-cloned boar exhibited typical diabetic symptoms that could be controlled by insulin administration.

Following the successful rearing of this founder Tg-cloned boar, we removed one testis at 8 months and the other at 12 months. Epididymal sperm was collected from each testis and cryopreserved using the method described by Kikuchi *et al.* [6] with a slight modification. After thawing, sperm samples were used for IVF and intrafallopian insemination.

The fertilization capacities of the Tg-cloned boar sperm at 8 months (DM-8m) and 12 months (DM-12m) of age were compared with those of WT boar sperm via IVF using IVM oocytes. IVF was performed using previously reported methods [7, 8] with slight modifications. A preliminary experiment revealed the optimal insemination concentration was 1.0×10^6 cells/ml for IVF with the WT boar sperm. Therefore, we adopted this condition for IVF with the Tg-cloned boar sperm.

The fertilization rate with the Tg-cloned boar sperm was significantly ($P < 0.05$) lower than that with WT boar sperm: WT, 54.6%; DM-8m, 26.7%; DM-12m, 24.0%. IVF with the DM-8m sperm yielded rates of normal cleavage and blastocyst formation equivalent to IVF with WT sperm (Table 2). However, use of DM-12m sperm for IVF significantly reduced the rate of embryonic development (Table 2).

The blood glucose level of the founder Tg-cloned boar was maintained at slightly higher levels than normal to avoid hypoglycemic coma. The fact that the Tg boar was maintained under suboptimal conditions for more than 6 months may have had a negative influ-

ence on sperm quality. Reduced sperm quality in male diabetic patients has been reported by several groups [9, 10]. Paasch *et al.* (2011) [11] reported increased accumulation of eppin (epididymal proteinase inhibitor) protein complex components, such as clusterin, lactotransferrin and semenogelin-1, in the sperm plasma membranes of diabetic patients. They also noted a possible influence of this eppin accumulation on the fertilization capacity of the sperm. A morphological study by Baccetti *et al.* (2002) [12] of diabetic patients' sperm indicated an increased incidence of acrosomal abnormalities and aberrations of the sperm nuclei and tails. Together, these results suggest that the sperm quality of the Tg-cloned boar was adversely affected by diabetic symptoms.

The fertilization rate of porcine IVF has been reported to increase with sperm concentration [13, 14]. Thus, we examined whether elevated Tg-cloned boar sperm concentrations, above the level optimal for WT boar sperm (1.0×10^6), could improve the outcome of IVF. We found that embryo cleavage rates and blastocyst formation rates were highest at 2.5×10^6 cells/ml and 5×10^6 cells/ml for the DM-8m and DM-12m sperm, respectively (Table 3). Both of these concentrations are far above the optimal sperm concentration for WT boars in our experimental settings. These results may be coincident with the deteriorated fertility of the DM-12m sperm.

Next, we examined whether live piglets could be produced by IVF using cryopreserved Tg-cloned boar sperm. DM-12m sperm was used for IVF to verify the utility of the reduced-quality cryopreserved sperm. The insemination concentration was set at 5×10^6 cells/ml, and the resultant embryos at either the 1–8-cell stage (days 1–3) or the blastocyst stage (days 5–6) were transferred to estrus-synchronized recipients. In total, 319 embryos at the 1–8-cell stage were transferred into four recipient gilts; three became pregnant and gave birth to 22 live piglets. Seven of the live piglets (31.8%) were transgenic, carrying the human mutant HNF-1 α transgene (Table 4). All of the Tg piglets exhibited hyperglycemia similar to the founder Tg-cloned boar, except for three of the Tg piglets that died before one week of

Table 2. Efficiency of fertilization and development of porcine oocytes fertilized *in vitro* with cryopreserved boar sperm

Type of sperm	Inseminated sperm concentration ($\times 10^6$ cells/ml)	No. of oocytes			No. of oocytes		
		Examined after insemination	Fertilized (%)	Normally fertilized (%)	Cultured after insemination	Normally cleaved (%)	Developed to the blastocyst stage (%)
WT	1.0	97	53 (54.6) ^a	25 (47.2) ^a	69	42 (60.9) ^a	32 (46.4) ^a
DM-8m	1.0	45	12 (26.7) ^b	10 (83.3)	37	19 (51.4) ^a	14 (37.8) ^a
DM-12m	1.0	125	30 (24.0) ^b	28 (93.3) ^b	83	23 (27.7) ^b	14 (16.9) ^b

^{ab} Significant differences ($P < 0.05$).

Table 3. Determination of optimal sperm concentration for *in vitro* fertilization of cryopreserved diabetic boar sperm

Type of sperm	Inseminated sperm concentration ($\times 10^6$ cells/ml)	No. of oocytes			No. of oocytes		
		Examined after insemination	Fertilized (%)	Normally fertilized (%)	Cultured after insemination	Normally cleaved (%)	Developed to the blastocyst stage (%)
DM-8m	1.0	45	12 (26.7) ^a	10 (83.3)	37	19 (51.4)	14 (37.8)
	2.5	125	86 (68.8) ^b	45 (52.3)	71	48 (67.6) ^a	41 (57.7)
	5.0	129	71 (55.0) ^b	45 (63.4)	66	31 (47.0) ^b	30 (45.5)
DM-12m	1.0	125	30 (24.0) ^a	28 (93.3)	83	23 (27.7) ^a	14 (16.9) ^a
	2.5	144	60 (41.7) ^b	51 (85.0)	95	43 (45.3) ^b	33 (34.7) ^b
	5.0	112	70 (62.5) ^c	58 (82.9)	67	38 (56.7) ^b	34 (50.7) ^b

^{ab, ac, bc} Significant differences ($P < 0.05$).

Table 4. Production of offspring by *in vitro* fertilization and intrafallopian insemination of cryopreserved diabetic boar sperm

Methods	Recipients	No. of embryos transferred	No. of live piglets (tg piglets included)	No. of stillborn piglets (tg piglets included)	Proportion of tg piglets/litter (%)	Average (mean \pm SEM) body weight of piglets at birth (kg)
IVF-1 ^a	P57	70	11 (4)	3 (0)	4/14 (28.6)	0.56 \pm 0.05
	P84	112	7 (2)	0 (0)	2/7 (28.6)	1.09 \pm 0.06
	P162	93	4 (1)	4 (3)	4/8 (50.0)	0.70 \pm 0.13
	P58 ^c	44	-	-	-	-
IVF-2 ^b	P99	20	4 (1)	3 (1)	2/7 (28.6)	0.75 \pm 0.10
	P135	15	5 (2)	0 (0)	2/5 (40.0)	0.84 \pm 0.09
Intrafallopian insemination	B47	10 ^d	6 (4)	2 (2)	6/8 (75.0)	1.07 \pm 0.05
	B45 ^c	10 ^d	-	-	-	-
	B46 ^c	8 ^d	-	-	-	-
	B51 ^c	14 ^d	-	-	-	-

^a Embryos were transferred at the 1–8-cell stage. ^b Embryos were transferred at the blastocyst stage. ^c Returned to estrus. ^d No. of ovulations.

age. Four of the Tg piglets developed to the weaning stage.

A total of 35 blastocysts produced by IVF were transferred into two recipients, both of which became pregnant. The gilts produced 9 live piglets, of which three (33.3%) were transgenic (Table 4). One of those developed to the weaning stage and exhibited hyperglycemia.

These results demonstrated that DM-12m sperm could be used to produce viable piglets through IVF despite reduced fertility.

Piglets were also produced by intrafallopian insemination using cryopreserved Tg-cloned boar sperm. DM-8m sperm, which exhibited better fertilization capacity in IVF, was used to minimize the risk of infertility in this *in vivo* experiment. Insemination of four ovulation-induced gilts resulted in one pregnancy, which produced four live (66.7%) Tg piglets out of six farrowed (Table 4). Three of the four Tg piglets developed to the weaning stage and exhibited hyperglycemia.

In this study, we demonstrated that IVF and intrafallopian insemination using cryopreserved epididymal sperm were effective in reproducing the diabetes model Tg pig. Production of offspring through artificial reproductive technology was possible even using reduced-quality sperm from the founder Tg boar; therefore, this approach should be applicable for other pig strains that model human diseases.

Materials and Methods

Animal care

The Institutional Animal Care and Use Committee of Meiji University approved all animal experiments in this study (IACUC 09-0006).

In vitro maturation of porcine oocytes

SCNT and IVF were performed using IVM oocytes. Porcine ovaries were collected at a local abattoir and transported to the laboratory in Dulbecco's phosphate-buffered saline (DPBS; Nissui Pharmaceutical, Tokyo, Japan) containing 75 µg/ml potassium penicillin G, 50 µg/ml streptomycin sulfate, 2.5 µg/ml amphotericin B and 0.1% (w/v) polyvinyl alcohol (PVA). Cumulus-oocyte complexes (COCs) were collected by aspiration from ovarian antral follicles with a diameter of 3.0–6.0 mm. COCs with at least three layers of compacted cumulus cells were selected and cultured in NCSU23 medium [15] supplemented with 0.6 mM cysteine, 10 ng/ml epidermal growth factor (EGF), 10% (v/v) porcine follicular fluid, 75 µg/ml potassium penicillin G, 50 µg/ml streptomycin sulfate, 10 IU/ml equine chorionic gonadotropin (eCG; ASKA Pharmaceutical, Tokyo, Japan) and 10 IU/ml human chorionic gonadotropin (hCG; ASKA Pharmaceutical). The COCs were cultured for 22 h with hormones in a humidified atmosphere of 5% CO₂ and 95% air at 38.5 C, followed by additional culture for 18–20 h without hormones in a humidified atmosphere of 5% CO₂, 5% O₂ and 90% N₂ at 38.5 C.

Production of Tg embryos by somatic cell cloning

Porcine fetal fibroblast cells (#111-4) carrying an expression vector for the mutant human HNF-1α cDNA (HNF-1αP291fsinsC), which had been established in our previous study [4], were used as nuclear donor cells. SCNT was performed using IVM oocytes as recipient cytoplasm as described elsewhere [5]. SCNT embryos were cultured in porcine zygote medium-5 (PZM-5; Research Institute for the Functional Peptides, Yamagata, Japan) in a humidified atmosphere of 5% CO₂, 5% O₂ and 90% N₂ at 38.5 C for 1 or 2 days, and then they were transferred into an estrus-synchronized recipient.

Cryopreservation of boar spermatozoa from epididymides

The cauda epididymides of the founder Tg-cloned boar and a WT boar (17 months old) were removed under general anesthesia and transferred to the laboratory at ambient temperature. Luminal fluid containing spermatozoa was extruded from the distal portion of each cauda epididymis by air pressure from a syringe, followed by perfusion with approximately 10 ml of collecting solution [6]. The recovered sperm suspension was diluted to a concentration of 2.0×10^9 cells/ml by adding collecting solution. The sperm suspension was then cooled down from 25 C to 15 C over 60 min (average cooling rate: 0.17 C/min). After incubation for 2 h at 15 C, the sperm suspension was centrifuged at $800 \times g$ for 10 min at 15 C and the supernatant was discarded. Precipitated spermatozoa were resuspended in equal amounts of Niwa and Sasaki Freezing (NSF)-I extender [6]. The sperm suspension was again cooled down from 15 C to 5 C over 120 min (average cooling rate: 0.08 C/min) and was then diluted to a concentration of 2.0×10^9 cells/ml with NSF-I extender. It was finally mixed with an equal volume of NSF-II extender containing 6% (v/v) glycerol [6]. The sperm suspension (0.2–0.3 ml) was loaded in 0.5-ml plastic straws (Cryo Bio System, Paris, France). The straws were placed in liquid nitrogen vapor (–150 C) approximately 4 cm above the surface of liquid nitrogen for 20 min and were finally plunged into liquid nitrogen.

IVF

IVF was performed using IVM oocytes with expanded cumulus cells [16]. A straw containing frozen sperm was thawed by immersion in warm water (37 C) for 30 seconds. The sperm were then suspended in 5 ml DPBS supplemented with 0.1% bovine serum albumin (Wako Pure Chemical Industries, Osaka, Japan) and washed three times by centrifugation at $1,000 \times g$ for 4 min. After washing, the sperm pellets were resuspended in porcine fertilization medium (PFM; Research Institute for the Functional Peptides) at a concentration of 1×10^7 cells/ml.

For insemination, 20 COCs that had been matured *in vitro* were placed in a 100-µl drop of PFM containing spermatozoa ($1.0\text{--}5.0 \times 10^6$ cells/ml); the oocytes and sperm were incubated for 8 h at 38.5 C in a humidified atmosphere containing 5% CO₂, 5% O₂ and 90% N₂. After insemination, the eggs were transferred to Tyrode lactose medium containing 10 mM Hepes and 0.3% (w/v) polyvinylpyrrolidone (Hepes-TL-PVP); cumulus cells and excess sperm were removed by gentle pipetting. Eggs that showed release of one or more polar bodies with normal cytoplasmic morphology were cultured (20–30 eggs/20–30 µl drop) in PZM-5 under paraffin oil (Kanto Chemical, Tokyo, Japan) in a plastic petri dish maintained in an atmosphere of 5% CO₂, 5% O₂ and 90% N₂ at 38.5 C until transfer. Eggs were cultured beyond the morula stage by adding 10% (v/v) fetal calf serum to the medium.

Some eggs were fixed in 1:3 acetic acid:methanol after 12 h of culture and then stained with 1% aceto-orcein. Eggs with two pronuclei and two polar bodies were considered to have undergone normal fertilization. Other categories of fertilized eggs were identified as polyspermic: eggs with two pronuclei, two polar bodies and a swollen sperm head(s) and eggs with three or more pronuclei.

Embryo transfer

Crossbred (Large White / Landrace X Duroc) prepubertal gilts weighing 100–105 kg were used as recipients. To induce estrus in the gilts, 1000 IU of eCG was injected intramuscularly, followed by an injection of 1500 IU hCG (Kyoritsu Seiyaku Corporation, Tokyo, Japan) 66 h later.

SCNT embryos were transferred at the 1-cell (day 1) or 2–8-cell (day 2) stages into the oviducts of estrus-synchronized recipient gilts by midventral laparotomy under general anesthesia [5]. Transfer of *in vitro*-fertilized embryos was conducted at 1–8-cell (days 1–3) or blastocyst (days 5–6) stage. Embryos on days 1–2, day 3 and days 5–6 were respectively transferred to recipients at 51–54 h, 75–78 h and 147–150 h after the hCG injection. Pregnant recipients were allowed to farrow, and piglets obtained were raised with the standard diet and water *ad libitum*.

Intrafallopian insemination

The gilts used for the intrafallopian insemination experiment were induced to ovulate by an injection of 1000 IU eCG, followed 72 h later by administration of 1500 IU hCG. Intrafallopian insemination was performed by midventral laparotomy approximately 46 h after hCG injection. The ovaries of estrus-induced recipients were examined to confirm that ovulation had occurred. Frozen-thawed epididymal sperm suspended in Beltsville thawing solution [17] at a concentration of 2.7×10^7 cells/0.1 ml were injected into both ampullae of the fallopian

tubes using a 3.5 Fr catheter (Tom Cat Catheter, Tyco Healthcare Group, Mansfield, MA, USA) with a syringe. The proportion of sperm with progressive motility was 30%.

Control of blood glucose levels in the diabetic founder boar

Blood glucose levels were measured daily (morning and evening) with a glucose test meter (GLUCOCARD GT-1820, Arkray, Kyoto, Japan) using blood samples from the ear vein. The diabetic founder pig received a subcutaneous injection of insulin glargine (0.5–1.1 U/kg) at the time of feeding in the morning. Blood glucose levels were measured again 60–90 min after feeding, and a subcutaneous injection of regular insulin (0–0.2 U/kg) was given to maintain a blood glucose level of approximately 200 mg/dl.

Biochemical analysis of blood components

Venous blood samples were collected in tubes containing heparin to determine the concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (CRE), glucose (GLU), total cholesterol (T-CHO), triglyceride (TG), total protein (TP), sodium (Na), potassium (K) and chloride (Cl) using a dry-chemistry analyzer (FUJI DRI-CHEM 7000, FUJIFILM Corporation, Tokyo, Japan). The concentration of 1,5-anhydroglucitol (1,5-AG) was determined using the enzymatic method (SRL, Tokyo, Japan).

Determination of transgenic offspring

Determination of transgenic offspring was performed using PCR. Genomic DNA was extracted from offspring tail tissue, purified with a DNeasy Blood & Tissue Kit (QIAGEN, Tokyo, Japan) and amplified using TaKaRa Ex Taq (Takara Bio, Shiga, Japan) with the following set of primers: 5'-AGGACCTGAGCCTGCCGAGCAAC-3' and 5'-AGGGCTCTCCATAGGCCAGGCT-3'. The PCR conditions were as follows: 94 C for 3 min, followed by 25 cycles of 94 C for 30 s, 60 C for 15 s and 72 C for 20 s.

Statistics

Statistical analyses were performed using the SPSS 16.0 software (SPSS, Chicago, IL, USA). Differences in the rates of fertilization and embryo development between the DM sperm and control WT sperm were analyzed using a χ^2 test.

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Re-

search (C) (#23500505) from the Ministry of Education, Culture, Sports, Science and Technology/Japan Society for the Promotion of Science and by the Program for Promotion of Basic Research Activities for Innovative Bioscience (PROBRAIN), Tokyo, Japan.

References

1. Lunney JK. Advances in swine biomedical model genomics. *Int J Biol Sci* 2007; 3: 179–184. [Medline]
2. Whyte JJ, Prather RS. Genetic modifications of pigs for medicine and agriculture. *Mol Reprod Dev* 2011; 78: 879–891. [Medline]
3. Luo Y, Lin L, Bolund L, Jensen TG, Sorensen CB. Genetically modified pigs for biomedical research. *J Inherit Metab Dis* 2012; 35: 695–713. [Medline]
4. Umeyama K, Watanabe M, Saito H, Kurome M, Tohi S, Matsunari H, Miki K, Nagashima H. Dominant-negative mutant hepatocyte nuclear factor 1 α induces diabetes in transgenic-cloned pigs. *Transgenic Res* 2009; 18: 697–706. [Medline]
5. Matsunari H, Onodera M, Tada N, Mochizuki H, Karasawa S, Haruyama E, Nakayama N, Saito H, Ueno S, Kurome M, Miyawaki A, Nagashima H. Transgenic-cloned pigs systemically expressing red fluorescent protein, Kusabira-Orange. *Cloning Stem Cells* 2008; 10: 313–323. [Medline]
6. Kikuchi K, Nagai T, Kashiwazaki N, Ikeda H, Noguchi J, Shimada A, Soloy E, Kaneko H. Cryopreservation and ensuing *in vitro* fertilization ability of boar spermatozoa from epididymides stored at 4 degrees C. *Theriogenology* 1998; 50: 615–623. [Medline]
7. Funahashi H, Nagai T. Regulation of *in vitro* penetration of frozen-thawed boar spermatozoa by caffeine and adenosine. *Mol Reprod Dev* 2001; 58: 424–431. [Medline]
8. Yoshioka K, Suzuki C, Itoh S, Kikuchi K, Iwamura S, Rodriguez-Martinez H. Production of piglets derived from *in vitro*-produced blastocysts fertilized and cultured in chemically defined media: effects of theophylline, adenosine, and cysteine during *in vitro* fertilization. *Biol Reprod* 2003; 69: 2092–2099. [Medline]
9. Vignon F, Le Faou A, Montagnon D, Pradignac A, Cranx C, Winiszewsky P, Pinget M. Comparative study of semen in diabetic and healthy men. *Diabete Metab* 1991; 17: 350–354. [Medline]
10. Handelsman DJ, Conway AJ, Boylan LM, Yue DK, Turtle JR. Testicular function and glycaemic control in diabetic men. A controlled study. *Andrologia* 1985; 17: 488–496. [Medline]
11. Paasch U, Heidenreich F, Pursche T, Kuhlisch E, Kettner K, Grunewald S, Kratzsch J, Dittmar G, Glander HJ, Hoffack B, Kriegel TM. Identification of increased amounts of eppin protein complex components in sperm cells of diabetic and obese individuals by difference gel electrophoresis. *Mol Cell Proteomics* 2011; 10: M110.007187. [Medline]
12. Baccetti B, La Marca A, Piomboni P, Capitani S, Brunì E, Petraglia F, De Leo V. Insulin-dependent diabetes in men is associated with hypothalamo-pituitary derangement and with impairment in semen quality. *Hum Reprod* 2002; 17: 2673–2677. [Medline]
13. Wang WH, Niwa K, Okuda K. *In-vitro* penetration of pig oocytes matured in culture by frozen-thawed ejaculated spermatozoa. *J Reprod Fertil* 1991; 93: 491–496. [Medline]
14. Yi YJ, Park CS. Effects of sperm concentrations and culture media on fertilization and development of *in vitro* matured pig oocytes. *Zygote* 2004; 12: 263–267. [Medline]
15. Petters RM, Wells KD. Culture of pig embryos. *J Reprod Fertil Suppl* 1993; 48: 61–73. [Medline]
16. Maehara M, Matsunari H, Honda K, Nakano K, Takeuchi Y, Kanai T, Matsuda T, Matsumura Y, Hagiwara Y, Sasayama N, Shirasu A, Takahashi M, Watanabe M, Umeyama K, Hanazono Y, Nagashima H. Hollow fiber vitrification provides a novel method for cryopreserving *in vitro* maturation/fertilization-derived porcine embryos. *Biol Reprod* 2012; 87: 133–140. [Medline]
17. Pursel VG, Johnson LA. Freezing of boar spermatozoa: fertilizing capacity with concentrated semen and a new thawing procedure. *J Anim Sci* 1975; 40: 99–102. [Medline]

